Status:
COMPLETED
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer. During a 4 week ...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- histologically or cytologically confirmed pancreatic cancer with measurable or non-measurable metastatic disease;
- ECOG performance status of 0-1.
Exclusion
- local, or locally advanced, pancreatic cancer;
- prior systemic treatment for metastatic pancreatic cancer;
- \<=6 months since last adjuvant chemotherapy;
- other malignancies within last 5 years, except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
467 Patients enrolled
Trial Details
Trial ID
NCT00652366
Start Date
May 1 2008
End Date
February 1 2012
Last Update
February 11 2015
Active Locations (89)
Enter a location and click search to find clinical trials sorted by distance.
1
Buenos Aires, Argentina, C1264AAA
2
Rosario, Argentina, S2000PBJ
3
San Juan Bautista, Argentina, B1878DVB
4
Santa Fe, Argentina, 03000